Clinical trialPhase 2Recruiting
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 21 June 2018
- Expected end
- 1 June 2032
- Enrollment
- 125 participants
- Sites
- 1
- Primary outcomes
- Completion of all intended neoadjuvant therapy and surgical therapy
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 8 January 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Detailed description public domain (ClinicalTrials.gov)
Patients will receive standard chemotherapy and chemoradiation for pancreatic cancer. The study intervention is an adaptive approach which modifies systemic therapy based on clinical assessments of treatment response. Treatment response will be assessed by imaging (CT scan), biomarker \[serum cancer antigen (CA)19-9\] and performance status assessment \[short physical performance battery (SPPB) and Center for Epidemiologic Studies Depression Scale (CES-D) evaluations\] at the first restaging assessment. Treatment response will be categorized as: 1. response; 2. stable disease; 3. local disease progression; 4. metastatic disease progression. After the first restaging evaluation, patients who demonstrate: 1. a response will be maintained on the same chemotherapy; 2. stable disease will be changed to a defined alternative chemotherapy or molecular profile-directed therapy; 3. local progression will receive chemoradiation; 4. metastatic disease will be removed from the trial. Patients who complete four months of chemotherapy, will be treated with chemoradiation (50.4 Gray (Gy) in 28 fractions). In the absence of local disease progression deemed inoperable, or metastatic disease progression, patients will be offered surgical resection. Patients who did not receive four months of systemic therapy in the neoadjuvant setting will be offered four months of adjuvant therapy at the discretion of their treating physicians.